ArticleScientific reports2025
Using partially shared radiomics features to simultaneously identify isocitrate dehydrogenase mutation status and epilepsy in glioma patients from MRI images.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic performance of deep learning for predicting glioma isocitrate dehydrogenase and 1p/19q co-deletion in MRI: a systematic review and meta-analysis.European radiology · 2026Pooled it
- Nomogram combining visual imaging and radiomics analysis for distinguishing diffuse hemispheric glioma, H3 G34-mutant from adult-type diffuse high-grade gliomas.Neuroradiology · 2026Article
- AI in epilepsy neuroimaging.Current opinion in neurology · 2026Review
- Machine learning-based models for predicting glioma-associated epilepsy: a systematic review and meta-analysis.Discover oncology · 2025Article
- Research progress in glioma-related epilepsy (Review).Biomedical reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Prediction of isocitrate dehydrogenase (IDH) mutation status and epilepsy occurrence are important to glioma patients. Although machine learning models have been constructed for both issues, the correlation between them has not been explored. Our study aimed to exploit this correlation to improve the performance of both of the IDH mutation status identification and epilepsy diagnosis models in patients with glioma II-IV. 399 patients were retrospectively enrolled and divided into a training (n = 279) and an independent test (n = 120) cohort. Multi-center dataset (n = 228) from The Cancer Imaging Archive (TCIA) was used for external test for identification of IDH mutation status. Region of interests comprising the entire tumor and peritumoral edema were automatically segmented using a pre-trained deep learning model. Radiomic features were extracted from T1-weighted, T2-weighted, post-Gadolinium T1 weighted, and T2 fluid-attenuated inversion recovery images. We proposed an iterative approach derived from LASSO to select features shared by two tasks and features specific to each task, before using them to construct the final models. Receiver operating characteristic (ROC) analysis was employed to evaluate the model. The IDH mutation identification model achieved area under the ROC curve (AUC) values of 0.948, 0.946 and 0.860 on the training, internal test, and external test cohorts, respectively. The epilepsy diagnosis model achieved AUCs of 0.924 and 0.880 on the training and internal test cohorts, respectively. The proposed models can identify IDH status and epilepsy with fewer features, thus having better interpretability and lower risk of overfitting. This not only improves its chance of application in clinical settings, but also provides a new scheme to study multiple correlated clinical tasks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.